In vitro growth of murine T cells

Rosenberg, Steven A.; Spiess, Paul J.; Schwarz, Susan

doi:10.1016/0008-8749(80)90211-7

Cited by 26 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shortly after reading this paper, I switched laboratory efforts to determine whether we could grow human lymphocytes in vitro with the goal of directing these reactivities against cancers. Producing sufficient IL-2 for experiments using mouse and human lymphocytes was difficult and it took about 4 months for us to develop approaches to produce IL-2 from mouse spleens and subsequently from human spleens and human peripheral lymphocytes (Rosenberg et al 1978a , b , 1980a ; b ; Yron et al 1980 ; Strausser and Rosenberg 1978 ). My lab was small at that point with two post-doctoral fellows, surgeons who had come to the NIH to receive training, as well as two technicians, Susan Schwartz and Paul Speiss, who with me were conducting these experiments.…”

Section: Early Research At the Nihmentioning

confidence: 99%

A Journey in Science: Immersion in the search for effective cancer immunotherapies

Rosenberg

2021

Mol Med

Self Cite

View full text Add to dashboard Cite

Real innovations in medicine and science are historic and singular; the stories behind each occurrence are precious. At Molecular Medicine we have established the Anthony Cerami Award in Translational Medicine to document and preserve these histories. The monographs recount the seminal events as told in the voice of the original investigators who provided the crucial early insight. These essays capture the essence of discovery, chronicling the birth of ideas that created new fields of research and launched trajectories that persisted and ultimately influenced how disease is prevented, diagnosed, and treated. In this volume, the Cerami Award Monograph is by Steven A. Rosenberg, Chief of Surgery at the National Cancer Institute in Bethesda, Maryland, USA. A pioneer in the development of immunotherapies and gene therapies for advanced cancers, this is the story of Dr. Rosenberg’s scientific journey.

show abstract

Section: Early Research At the Nihmentioning

confidence: 99%

A Journey in Science: Immersion in the search for effective cancer immunotherapies

Rosenberg

2021

Mol Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…A comprehensive discussion of this work is beyond the scope of this review. Briefly, however, the initial discovery of IL-2 as a T-cell growth factor [87] and parallel discoveries that IL-2 can mediate the in vitro expansion of T-cells with specific immunologic functions [115,127] were early catalysts for this work. These findings prompted in vivo studies that provided compelling evidence that the growth of transplantable tumors in mice can be inhibited by the direct administration of exogenous IL-2 [114].…”

Section: Interleukin-2 Immunotherapy For Cancermentioning

confidence: 98%

Interleukin-2 Immunotherapy and AIDS-Related Cytomegalovirus Retinitis

Dix

Cousins²

2004

CHR

View full text Add to dashboard Cite

Cytokines are small proteins produced by T lymphocytes that mediate immune responses. Those produced by the CD4+ Th1 subset induce cell-mediated immunity, whereas those produced by the CD4+ Th2 subset are more efficient at stimulating immunoglobulin production. The goal of cytokine immunotherapy is prevention or reduction of disease progression through stimulation of cell-mediated immunity (i.e., immune reconstitution) by administration of an exogenous Th1 cytokine such as interleukin-2 (IL-2). Cytokine immunotherapy has its origins in cancer immunobiology where IL-2 has been used successfully to manage several human cancers (metastatic melanoma, acute myelogenous leukemia, and metastatic renal cell carcinoma). More recent work has demonstrated cytokine immunotherapy to be effective at improving immune responses in patients with HIV-1 disease. To explore cytokine immunotherapy for sight-threatening AIDS-related human cytomegalovirus (HCMV) retinitis, we developed a mouse model of experimental murine cytomegalovirus (MCMV) retinitis that employs mice with MAIDS, a retrovirus-induced immunodeficiency syndrome. Systemic cytokine immunotherapy with IL-2, but not with interleukin-12 (IL-12), provides absolute protection against MAIDS-related MCMV retinitis by stimulation of the perforin-mediated pathway of cytotoxicity used by natural killer cells and cytotoxic CD8+ T cells to kill virus-infected cells. Our findings warrant additional studies on the use of cytokine immunotherapy for management of HCMV retinitis (and possibly other opportunistic infections) during HIV-1-induced immunodeficiency. We envision systemic cytokine immunotherapy as an altemative or adjunct to traditional antiviral chemotherapy for optimal management of AIDS-related HCMV retinitis.

show abstract

“…There are currently many preclinical and clinical studies evaluating the potential of FL as an adjuvant for cancer immunotherapy. Interleukin 2 (IL-2) was first recognized as a promising immunotherapeutic agent after high dose administration of IL-2 in cancer patients resulted in tumor regression [141][142][143]. The action of IL-2 is different to previously discussed adjuvants as it does not have a direct effect on cancer cells but instead alters the host immune response and supports the effector functions induced by T cell responses [144].…”

Section: Ajcc Stage IV Melanomamentioning

confidence: 99%

Design of Peptide-Based Vaccines for Cancer

Pietersz

Pouniotis²,

Apostolopoulos³

2006

CMC

View full text Add to dashboard Cite

The immune system responds efficiently to bacteria, viruses and other agents however, the immune response to cancers is not as effective. In most cases other than specific genetic rearrangements leading to non-self proteins such as in leukemia and idiotypes in lymphoma, tumor associated proteins are self proteins and are not recognized by the immune system to prevent malignancy. In most cancers, patients develop antibodies and/or CTL-precursors to tumor associated antigens but are not effective in generating a therapeutic immune response. Adjuvants have been used with either whole tumors, subunits or peptides with the aim of increasing their immunity. Whole tumor antigens have certain advantages associated with it, such as ready availability as recombinant proteins, potential epitopes that can be presented by a number of MHC class I/II alleles and antibody development. The methods of identification of CD8 and CD4 epitopes either by use of epitope prediction algorithms or use of transgenic mice has made the use of defined synthetic peptides more attractive. The possibility to synthesize long peptides and introduce multiple epitopes (CD4 or CD8) from single or multiple antigens makes peptide a viable alternative to whole proteins. As an alternative to totally synthetic peptide constructs or polymers, polytopes have been generated by genetic engineering methods. In addition, to deliver immunogens to and to activate DC, receptor-mediated delivery of peptides using antibodies, cytokines and carbohydrates have been used. This review will encompass the various strategies, preclinical and clinical applications in designing peptide-based vaccines for cancer.

show abstract

In vitro growth of murine T cells

Cited by 26 publications

References 15 publications

A Journey in Science: Immersion in the search for effective cancer immunotherapies

A Journey in Science: Immersion in the search for effective cancer immunotherapies

Interleukin-2 Immunotherapy and AIDS-Related Cytomegalovirus Retinitis

Design of Peptide-Based Vaccines for Cancer

Contact Info

Product

Resources

About